# LSTA catalysts: LISATA THERAPEUTICS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/lsta/catalysts

> LISATA THERAPEUTICS, INC. (LSTA) has 2 upcoming catalysts. The next is the MAR005 topline data readout, mid-2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for LSTA?

LISATA THERAPEUTICS, INC. (LSTA) has 2 upcoming catalysts. The next is the MAR005 topline data readout, mid-2027. SEC Form 10-Q: "We expect to report topline data from Part B of the Phase 2b study of MAR001 in sHTG in the second half of 2027 and to complete dose selection for a Phase 3 clinical trial of MAR005 in mid-2027." [Calendar and source filings](https://sec-api.dev/companies/lsta/catalysts)

Source: SEC Form 10-Q, accession 0000320017-26-000044, https://www.sec.gov/Archives/edgar/data/320017/000032001726000044/lsta-20260930.htm (retrieved 2026-11-14). Last confirmed 2026-11-13. Cite: https://sec-api.dev/companies/lsta/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | LISATA THERAPEUTICS, INC. |
| Ticker | LSTA (Nasdaq) |
| SEC CIK | 320017 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/lsta |

## Cash runway

Cash $282.7M as of 2026-09-30; quarterly burn $12.7M; about 66.9 months of runway at that rate (XBRL company facts, accession 0000320017-26-000044).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2023 | [Certepetide trial start](https://sec-api.dev/pdufa/certepetide) | LSTA |  | completed | "Timing: Enrollment commenced April 2023 Appendix 51 iLSTA: Phase 1b/2a trial in locally advanced PDAC with chemo & IO" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/320017/000032001725000004/lstacorporatepresentatio.htm)) |
| November 12, 2024 | [LISATA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/lsta/catalysts) | LSTA |  | completed | "Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/320017/000032001724000057/ex991earningsrelease3q24fi.htm)) |
| Jan 2025 | [Certepetide interim data readout](https://sec-api.dev/pdufa/certepetide) | LSTA |  | scheduled | "Following the completion of enrollment in the fourth quarter of 2023, data from an interim analysis of the 95 Cohort A patients (single dose of certepetide administered with SoC) will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in January of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/320017/000032001724000057/ex991earningsrelease3q24fi.htm)) |
| February 27, 2025 | [LISATA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/lsta/catalysts) | LSTA |  | completed | "Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/320017/000032001725000010/ex991earningsrelease4q24.htm)) |
| mid-2025 | [Certepetide topline data readout](https://sec-api.dev/pdufa/certepetide) | LSTA |  | scheduled | "The Company achieved complete enrollment in first-line CCA nearly six months ahead of plan, accelerating anticipated topline data readout to mid-2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/320017/000032001725000028/ex991earningsrelease1q25fi.htm)) |
| May 8, 2025 | [LISATA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/lsta/catalysts) | LSTA |  | completed | "Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/320017/000032001725000028/ex991earningsrelease1q25fi.htm)) |
| August 7, 2025 | [LISATA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/lsta/catalysts) | LSTA |  | completed | "Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/320017/000032001725000059/ex991earningsrelease2q25.htm)) |
| Q4 2025 | [Certepetide topline data readout](https://sec-api.dev/pdufa/certepetide) | LSTA |  | scheduled | "The Company achieved complete enrollment in first-line CCA nearly six months ahead of plan, accelerating anticipated topline data readout to fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/320017/000032001725000069/ex991earningsrelease3q25.htm)) |
| November 6, 2025 | [LISATA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/lsta/catalysts) | LSTA |  | completed | "Lisata Therapeutics Reports Third Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/320017/000032001725000069/ex991earningsrelease3q25.htm)) |
| April 5, 2026 | [Certepetide primary completion](https://sec-api.dev/pdufa/certepetide) | LSTA | Cholangiocarcinoma; Gallbladder Cancer; Gallbladder Carcinoma | completed | "NCT05712356 (A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-05 (ACTUAL); Lead Sponsor Lisata Therapeutics, Inc.; Results First Posted 2026-05-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05712356)) |
| May 26, 2026 | [Certepetide topline data readout](https://sec-api.dev/pdufa/certepetide) | LSTA | Cholangiocarcinoma; Gallbladder Cancer; Gallbladder Carcinoma | completed | "NCT05712356 (A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-05 (ACTUAL); Lead Sponsor Lisata Therapeutics, Inc.; Results First Posted 2026-05-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05712356?tab=results)) |
| mid-2027 | [MAR005 topline data readout](https://sec-api.dev/pdufa/mar005) | LSTA |  | scheduled | "We expect to report topline data from Part B of the Phase 2b study of MAR001 in sHTG in the second half of 2027 and to complete dose selection for a Phase 3 clinical trial of MAR005 in mid-2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/320017/000032001726000044/lsta-20260930.htm)) |
| Q4 2027 | [MAR002 topline data readout](https://sec-api.dev/pdufa/mar002) | LSTA |  | scheduled | "We expect to report topline data from the Phase 2 clinical trial in the fourth quarter of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/320017/000032001726000044/lsta-20260930.htm)) |

## Drugs

- [Certepetide](https://sec-api.dev/pdufa/certepetide): Cholangiocarcinoma
- [MAR002](https://sec-api.dev/pdufa/mar002): 
- [MAR005](https://sec-api.dev/pdufa/mar005): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/lsta/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LSTA catalysts: LISATA THERAPEUTICS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/lsta/catalysts

```bibtex
@misc{secapidev_companies_lsta_catalysts_20261116,
  title        = {LSTA catalysts: LISATA THERAPEUTICS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/lsta/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_lsta_catalysts_20261116","title":"LSTA catalysts: LISATA THERAPEUTICS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/lsta/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
